Imidazo<5,1-c>benzo-1,2,4-triazin | 16352-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: Imidazo<5,1-c>benzo-1,2,4-triazin
• 英文别名: benzo[e]imidazo[5,1-c][1,2,4]triazine；Benz[e]imidazo-[5,1-c]-1,2,4-triazine；imidazo[5,1-c][1,2,4]benzotriazine
• CAS: 16352-39-9
• 化学式: C₉H₆N₄
• 分子量: 170.173
• InChiKey: SXDJLLBJOODHJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES
  申请人：Stange Hans

  公开号：US20100120763A1

  公开（公告）日：2010-05-13

  The invention relates to imidazo[5,1-c][1,2,4]benzotriazine derivatives of formula I: which are inhibitors of phosphodiesterase 2 or 10 useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.

  本发明涉及式I的咪唑并[5,1-c][1,2,4]苯并三嗪衍生物：它们是磷酸二酯酶2或10的抑制剂，可用于治疗精神病等中枢神经系统疾病，以及例如肥胖、2型糖尿病、代谢综合征、葡萄糖耐受不良和疼痛。
• Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US11186582B2

  公开（公告）日：2021-11-30

  The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

  本发明提供了式 (I) 的化学实体： 其中 R1、R2、X、Y 和 Z 具有本文所述的任一值，以及包含这种化学实体的组合物；制造它们的方法；以及它们在本文所公开的各种方法中的用途，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由 PDE2 活性介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆症、神经退行性疾病和创伤依赖性功能丧失；治疗中风，包括中风康复期间的认知和运动障碍；促进神经保护和神经恢复；提高认知和运动训练的效率，包括动物技能训练方案；以及治疗外周疾病，包括血液病、心血管病、肠胃病和皮肤病。
• SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS
  申请人：Dart NeuroScience (Cayman) Ltd.

  公开号：EP3134413B1

  公开（公告）日：2019-09-11
• SUBSTITUTED [1,2,4]TRIAZOLO [1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS
  申请人：Dart Neuroscience (Cayman) Ltd

  公开号：EP3134413A1

  公开（公告）日：2017-03-01
• COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS
  申请人：Dart NeuroScience (Cayman) Ltd

  公开号：EP3597649B1

  公开（公告）日：2021-10-13